Webcast
1.00 CME/CE Credit
Kidney Disease in Primary Care: From Diagnosis to Referral
Do you ever struggle to determine which patients should be evaluated for chronic kidney disease (CKD) and whether to refer patients to nephrology? Then this session is for you! Join nephrology specialist Dr. Raghavan and primary care expert Dr. Vega as they discuss the role primary care clinicians can and should play in identifying patients with chronic kidney disease that should be managed with the help of a nephrologist. Faculty will discuss screening and diagnosis of CKD, how to recognize which patients may have rare or genetic causes of kidney disease requiring specialist evaluation, and the role of genetic testing in diagnosis of kidney disease.
CME/CE Information
1.00 AMA PRA Category 1 Credits, 1.00 ABIM MOC
Release Date: 2/16/2024
Expiration Date: 8/16/2024
Topics
Learning Objectives
- Apply the guidelines and process that PCPs should follow when referring patients to nephrologists
- Emphasize the impact that proper and timely referrals can have on patient outcomes, quality of life, and access to emerging therapeutics
- Emphasize the importance of family history, associated symptoms, etc. when considering CKD causality and provide referral guidance for patients for whom a genetic or hereditary disease is suspected
- Introduce genetic testing options and summarize potential patient outcomes and targeted treatment options
Faculty
Rajeev Raghavan, MD, M.Ed, FASN, FACP
Program Director, HCA Kingwood Internal Medicine
Adjunct Professor, University of Houston Fertitta Family College of Medicine
Clinical Associate Professor, Baylor College of Medicine
Charles Vega, MD, FAAFP
Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, UC Irvine School of Medicine
Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine
Learn MoreDisclosures
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Rajeev Raghavan MD M.Ed, FASN: Speaker, Bayer; Advisor, Reata; Consultant, GlaxoSmithKline, Travere
Moderator and other non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
CME/CE Information
AMA PRA Category 1 Credits
Accreditation Statement
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Credit Information
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Obtaining Credit
Supporters and Partners
Education Partners
Pri-Med Institute
American Kidney Fund, Inc.
Fine Print
The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions?
If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.